Handelen Caribou Biosciences, Inc. - CRBU CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.06 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 5.02 |
| Open* | 4.89 |
| 1-Jaarlijkse Verandering* | -44.56% |
| Dagelijks bereik* | 4.82 - 4.97 |
| 52 wekelijks bereik | 4.83-13.19 |
| Weekgemiddelde volume (10 dagen) | 595.92K |
| Gemiddeld volume (3 maanden) | 10.45M |
| Marktkapitalisatie | 304.05M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 61.30M |
| Omzet | 13.85M |
| EPS | -1.63 |
| Dividend (opbrengst %) | N/A |
| Beta | -100.00K |
| Volgende inkomsten datum | N/A |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Mar 17, 2023 | 4.91 | -0.02 | -0.41% | 4.93 | 5.02 | 4.80 |
| Mar 16, 2023 | 5.02 | -0.07 | -1.38% | 5.09 | 5.15 | 4.91 |
| Mar 15, 2023 | 5.15 | 0.10 | 1.98% | 5.05 | 5.25 | 5.02 |
| Mar 14, 2023 | 5.18 | -0.25 | -4.60% | 5.43 | 5.51 | 5.10 |
| Mar 13, 2023 | 5.30 | 0.25 | 4.95% | 5.05 | 5.34 | 5.02 |
| Mar 10, 2023 | 5.14 | -0.29 | -5.34% | 5.43 | 5.48 | 4.93 |
| Mar 9, 2023 | 5.48 | -0.35 | -6.00% | 5.83 | 5.85 | 5.33 |
| Mar 8, 2023 | 5.85 | 0.02 | 0.34% | 5.83 | 5.92 | 5.75 |
| Mar 7, 2023 | 5.86 | 0.03 | 0.51% | 5.83 | 6.04 | 5.70 |
| Mar 6, 2023 | 5.77 | -0.32 | -5.25% | 6.09 | 6.09 | 5.54 |
| Mar 3, 2023 | 6.09 | 0.17 | 2.87% | 5.92 | 6.11 | 5.86 |
| Mar 2, 2023 | 5.89 | 0.01 | 0.17% | 5.88 | 5.98 | 5.82 |
| Mar 1, 2023 | 6.00 | 0.03 | 0.50% | 5.97 | 6.13 | 5.88 |
| Feb 28, 2023 | 6.06 | 0.17 | 2.89% | 5.89 | 6.17 | 5.88 |
| Feb 27, 2023 | 5.97 | 0.16 | 2.75% | 5.81 | 6.09 | 5.78 |
| Feb 24, 2023 | 5.76 | -0.14 | -2.37% | 5.90 | 5.94 | 5.70 |
| Feb 23, 2023 | 6.07 | -0.12 | -1.94% | 6.19 | 6.23 | 5.93 |
| Feb 22, 2023 | 6.17 | 0.07 | 1.15% | 6.10 | 6.24 | 5.98 |
| Feb 21, 2023 | 6.09 | -0.39 | -6.02% | 6.48 | 6.73 | 6.08 |
| Feb 17, 2023 | 6.82 | 0.33 | 5.08% | 6.49 | 6.83 | 6.36 |
Caribou Biosciences, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Totale inkomsten | 5.788 | 12.361 | 9.598 |
| Inkomsten | 5.788 | 12.361 | 9.598 |
| Totale bedrijfskosten | 40.093 | 48.485 | 74.993 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 16.458 | 14.06 | 24.322 |
| Onderzoek & Ontwikkeling | 23.635 | 34.425 | 52.255 |
| Bedrijfsresultaat | -34.305 | -36.124 | -65.395 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 3.337 | -0.517 | 0.14 |
| Overige, Netto | 0 | 0.514 | -1.347 |
| Netto inkomen voor belastingen | -30.968 | -36.127 | -66.602 |
| Netto inkomen na belastingen | -23.431 | -34.308 | -66.923 |
| Netto inkomen voor extra. Posten | -23.431 | -34.308 | -66.923 |
| Netto inkomen | -23.431 | -34.308 | -66.923 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -23.431 | -34.308 | -66.923 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -23.431 | -34.308 | -66.923 |
| Verwaterd Netto Inkomen | -23.431 | -34.308 | -66.923 |
| Verwaterd Gewogen Gemiddelde Aandelen | 56.7092 | 56.7092 | 31.6632 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.41318 | -0.60498 | -2.11359 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.41318 | -0.60498 | -2.1461 |
| Ongebruikelijke uitgaven (inkomsten) | -1.584 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 1.586 | 1.476 | 3.977 | 2.559 | 2.664 |
| Inkomsten | 1.586 | 1.476 | 3.977 | 2.559 | 2.664 |
| Totale bedrijfskosten | 14.761 | 15.856 | 22.593 | 22.964 | 23.517 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 4.596 | 5.113 | 6.76 | 7.853 | 9.593 |
| Onderzoek & Ontwikkeling | 10.165 | 12.327 | 15.833 | 15.111 | 13.924 |
| Bedrijfsresultaat | -13.175 | -14.38 | -18.616 | -20.405 | -20.853 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.001 | 0.044 | 0.022 | 0.076 | 0.163 |
| Overige, Netto | 0.017 | 0.025 | -2.38 | 2.171 | 1.602 |
| Netto inkomen voor belastingen | -13.159 | -14.311 | -20.974 | -18.158 | -19.088 |
| Netto inkomen na belastingen | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Netto inkomen voor extra. Posten | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Netto inkomen | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Verwaterd Netto Inkomen | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Verwaterd Gewogen Gemiddelde Aandelen | 56.7092 | 10.2618 | 45.8896 | 60.4941 | 60.5462 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.23204 | -1.39459 | -0.45705 | -0.30547 | -0.31526 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.23204 | -1.54895 | -0.45705 | -0.30547 | -0.31526 |
| Ongebruikelijke uitgaven (inkomsten) | -1.584 | 0 | 0 |
- Jaarlijks
- Per kwartaal
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Totaal vlottende activa | 57.008 | 24.306 | 391.192 |
| Geldmiddelen en kortetermijnbeleggingen | 49.471 | 15.953 | 375.832 |
| Geldmiddelen & Equivalenten | 41.07 | 15.953 | 240.42 |
| Korte Termijn Investeringen | 8.401 | 0 | 135.412 |
| Totale Vorderingen, Netto | 3.982 | 5.16 | 8.124 |
| Accounts Receivable - Trade, Net | 0.841 | 1.478 | 2.641 |
| Prepaid Expenses | 3.182 | 2.433 | 6.565 |
| Other Current Assets, Total | 0.373 | 0.76 | 0.671 |
| Total Assets | 61.933 | 36.046 | 442.356 |
| Property/Plant/Equipment, Total - Net | 4.332 | 3.502 | 4.887 |
| Property/Plant/Equipment, Total - Gross | 6.59 | 6.598 | 8.964 |
| Accumulated Depreciation, Total | -2.258 | -3.096 | -4.077 |
| Long Term Investments | 0 | 7.626 | 45.302 |
| Other Long Term Assets, Total | 0.593 | 0.612 | 0.975 |
| Total Current Liabilities | 10.078 | 12.389 | 25.829 |
| Accounts Payable | 2.537 | 2.601 | 3.99 |
| Accrued Expenses | 5.653 | 8.151 | 12.089 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.654 | 0 |
| Other Current Liabilities, Total | 1.888 | 0.983 | 9.75 |
| Total Liabilities | 13.147 | 18.16 | 54.531 |
| Total Long Term Debt | 0 | 0.924 | 0 |
| Long Term Debt | 0 | 0.924 | 0 |
| Deferred Income Tax | 0.65 | 0.155 | 0.476 |
| Other Liabilities, Total | 2.419 | 4.692 | 28.226 |
| Total Equity | 48.786 | 17.886 | 387.825 |
| Preferred Stock - Non Redeemable, Net | 41.323 | 41.323 | 0 |
| Common Stock | 0.001 | 0.001 | 0.006 |
| Additional Paid-In Capital | 4.025 | 7.433 | 485.748 |
| Retained Earnings (Accumulated Deficit) | 3.437 | -30.871 | -97.794 |
| Total Liabilities & Shareholders’ Equity | 61.933 | 36.046 | 442.356 |
| Total Common Shares Outstanding | 56.7092 | 56.7092 | 60.2632 |
| Other Equity, Total | -0.135 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 155.925 | 142.967 | 449.047 | 391.192 | 368.01 |
| Geldmiddelen en kortetermijnbeleggingen | 145.924 | 129.524 | 435.31 | 375.832 | 353.731 |
| Geldmiddelen & Equivalenten | 145.924 | 129.524 | 435.31 | 240.42 | 147.63 |
| Totale Vorderingen, Netto | 5.825 | 8.407 | 7.785 | 8.124 | 6.037 |
| Accounts Receivable - Trade, Net | 1.049 | 0.832 | 2.431 | 2.641 | 1.868 |
| Prepaid Expenses | 3.096 | 3.759 | 5.189 | 6.565 | 7.276 |
| Other Current Assets, Total | 1.08 | 1.277 | 0.763 | 0.671 | 0.966 |
| Total Assets | 167.965 | 158.397 | 461.96 | 442.356 | 445.997 |
| Property/Plant/Equipment, Total - Net | 3.38 | 4.408 | 4.477 | 4.887 | 31.765 |
| Property/Plant/Equipment, Total - Gross | 6.695 | 7.952 | 8.282 | 8.964 | 36.15 |
| Accumulated Depreciation, Total | -3.315 | -3.544 | -3.805 | -4.077 | -4.385 |
| Long Term Investments | 7.626 | 7.626 | 7.626 | 45.302 | 44.758 |
| Other Long Term Assets, Total | 1.034 | 3.396 | 0.81 | 0.975 | 1.464 |
| Total Current Liabilities | 22.21 | 26.007 | 26.158 | 25.829 | 26.667 |
| Accounts Payable | 3.117 | 4.029 | 3.482 | 3.99 | 1.814 |
| Accrued Expenses | 10.929 | 11.034 | 12.288 | 12.089 | 11.215 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.655 | 0 | 0 | 0 | |
| Other Current Liabilities, Total | 7.509 | 10.944 | 10.388 | 9.75 | 13.638 |
| Total Liabilities | 53.504 | 55.938 | 57.559 | 54.531 | 74.2 |
| Total Long Term Debt | 0.926 | 0 | 0 | 0 | 0 |
| Long Term Debt | 0.926 | 0 | 0 | 0 | |
| Deferred Income Tax | 0.155 | 0.155 | 0.155 | 0.476 | 0.476 |
| Other Liabilities, Total | 30.213 | 29.776 | 31.246 | 28.226 | 47.057 |
| Total Equity | 114.461 | 102.459 | 404.401 | 387.825 | 371.797 |
| Preferred Stock - Non Redeemable, Net | 150.15 | 150.15 | 0 | 0 | 0 |
| Common Stock | 0.001 | 0.001 | 0.006 | 0.006 | 0.006 |
| Additional Paid-In Capital | 8.34 | 10.649 | 483.71 | 485.748 | 489.762 |
| Retained Earnings (Accumulated Deficit) | -44.03 | -58.341 | -79.315 | -97.794 | -116.882 |
| Total Liabilities & Shareholders’ Equity | 167.965 | 158.397 | 461.96 | 442.356 | 445.997 |
| Total Common Shares Outstanding | 56.7092 | 59.9708 | 60.0213 | 60.2632 | 60.6896 |
| Korte Termijn Investeringen | 135.412 | 206.101 | |||
| Other Equity, Total | -0.135 | -1.089 |
- Jaarlijks
- Per kwartaal
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Netto-inkomen/Beginsaldo | -23.431 | -34.308 | -66.923 |
| Geldmiddelen uit Operationele Activiteiten | -32.006 | -33.215 | -32.519 |
| Geldmiddelen uit Operationele Activiteiten | 0.751 | 0.9 | 0.984 |
| Niet-Geldelijke Posten | -1.059 | 0.016 | 4.353 |
| Cash Taxes Paid | 1.809 | 0.021 | 0.011 |
| Veranderingen in het Operationeel Kapitaal | -8.267 | 0.177 | 29.067 |
| Geldmiddelen uit Investeringsactiviteiten | 27.233 | 6.363 | -176.397 |
| Kapitaaluitgaven | -0.884 | -0.317 | -2.121 |
| Overige Cash Flow investeringsposten, Totaal | 28.117 | 6.68 | -174.276 |
| Geldmiddelen uit Financieringsactiviteiten | 0.172 | 1.735 | 433.429 |
| Uitgifte (Aflossing) van aandelen, netto | 0.217 | 1.848 | 432.398 |
| Uitgifte (Aflossing) van Schulden, Netto | -0.045 | -0.113 | 1.031 |
| Nettowijziging in Geldmiddelen | -4.601 | -25.117 | 224.513 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -13.159 | -27.47 | -48.444 | -66.923 | -19.088 |
| Cash From Operating Activities | 20.313 | 3.837 | -11.13 | -32.519 | -21.673 |
| Cash From Operating Activities | 0.221 | 0.451 | 0.711 | 0.984 | 0.308 |
| Non-Cash Items | 1.036 | 1.542 | 4.88 | 4.353 | 2.215 |
| Cash Taxes Paid | 0 | 0.011 | 0.011 | 0.011 | 0 |
| Cash Interest Paid | 0.001 | 0 | |||
| Changes in Working Capital | 32.215 | 29.314 | 31.723 | 29.067 | -5.108 |
| Cash From Investing Activities | -0.022 | -0.506 | -2.436 | -176.397 | -72.107 |
| Capital Expenditures | -0.022 | -0.506 | -1.436 | -2.121 | -0.723 |
| Other Investing Cash Flow Items, Total | 0 | 0 | -1 | -174.276 | -71.384 |
| Cash From Financing Activities | 109.68 | 110.286 | 432.969 | 433.429 | 0.99 |
| Issuance (Retirement) of Stock, Net | 109.799 | 109.957 | 431.938 | 432.398 | 0.99 |
| Issuance (Retirement) of Debt, Net | -0.119 | 1.031 | 1.031 | 1.031 | 0 |
| Net Change in Cash | 129.971 | 113.617 | 419.403 | 224.513 | -92.79 |
| Financing Cash Flow Items | -0.702 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| PFM Health Sciences, LP | Hedge Fund | 7.2754 | 4459783 | -1540217 | 2022-12-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.6832 | 4096777 | 277588 | 2022-12-31 | LOW |
| Haurwitz (Rachel E. Ph.D.) | Individual Investor | 5.4966 | 3369395 | 0 | 2022-08-01 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.2184 | 3198893 | 803423 | 2022-12-31 | LOW |
| Avidity Partners Management LP | Hedge Fund | 4.7025 | 2882600 | -290000 | 2022-12-31 | HIGH |
| Rokos Capital Management LLP | Hedge Fund | 4.4831 | 2748139 | 840630 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1939 | 2570827 | 26789 | 2022-12-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.1662 | 2553878 | -737020 | 2022-12-31 | LOW |
| Elmwood Wealth Management, INC. | Investment Advisor | 3.8569 | 2364240 | 0 | 2022-12-31 | LOW |
| EIDP Inc | Corporation | 3.3573 | 2058000 | -1093311 | 2022-05-31 | MED |
| BofA Global Research (US) | Research Firm | 3.008 | 1843902 | 1668395 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.3541 | 1443046 | -547 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.982 | 1214933 | 30615 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6819 | 1030987 | 45617 | 2022-12-31 | LOW |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 1.4575 | 893424 | -138016 | 2022-12-31 | LOW |
| Fidelity International | Investment Advisor | 1.404 | 860666 | 0 | 2022-12-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3944 | 854738 | 55247 | 2022-12-31 | HIGH |
| Maverick Capital, Ltd. | Hedge Fund | 1.0645 | 652542 | 0 | 2022-12-31 | MED |
| Tekla Capital Management LLC | Investment Advisor | 0.9252 | 567147 | 0 | 2022-12-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.9215 | 564855 | -1059 | 2022-12-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group 500000+
Handelaren
92000+
Actieve klanten per maand
$53000000+
Maandelijks beleggingsvolume
$30000000+
Probeer het nu Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Caribou Biosciences, Inc. Company profile
Over Caribou Biosciences, Inc.
Caribou Biosciences, Inc. is een in de Verenigde Staten gevestigd biotechnologiebedrijf in een klinische fase. Het bedrijf maakt gebruik van CRISPR (clustered regularly interspaced short palindromic repeats) om op immuuncellen gebaseerde therapeutica voor kanker te ontdekken en te ontwikkelen. Het bedrijf richt zich op de ontwikkeling van een pijplijn van genome-edited off-the-shelf CAR-T cel- en natural killer (NK) celtherapieën voor een reeks tumortypes. Het biedt ook licenties aan op zijn CRISPR-Cas9 basis-IP in verschillende domeinen, waaronder onderzoeksmiddelen, intern onderzoeksgebruik, diagnostica en industriële biotechnologie. De pijplijn van het bedrijf omvat CB-010, CB-011, CB-012 en CB-020.
| Industry: | Biotechnology & Medical Research (NEC) |
2929 7Th Street, Ste 120
94710
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen